Judge Rejected Dismissal of mRNA Vaccine Patent Suits
A federal judge allowed patent lawsuits against Pfizer, BioNTech, and Moderna to move forward in Delaware.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do patent lawsuits against vaccine manufacturers decrease your trust in pharmaceutical companies?
A federal judge has denied requests from Pfizer, BioNTech, and Moderna to dismiss patent infringement lawsuits. The legal action was brought by Bayer through its Monsanto unit regarding mRNA technology used in COVID-19 vaccines.
Why it matters
The ruling allows litigation to proceed concerning the ownership of foundational mRNA technology. The outcome of these cases could influence future licensing and patent strategies for pharmaceutical developers.
The litigation involves specific messenger RNA technology used in COVID-19 vaccines, identified under case numbers No. 1:26-cv-00012 against Moderna and No. 1:26-cv-00013 against Pfizer.
The players
Bayer CropScience LLC
This is a unit of the global life sciences company Bayer that focuses on agricultural and chemical products.
Moderna Inc
This is a biotechnology company known for its development of mRNA-based vaccines and therapies.
Pfizer Inc
This is a multinational pharmaceutical and biotechnology corporation that develops and produces vaccines and medicines.
The details
The US District Court for the District of Delaware presided over the dismissal motions filed by the vaccine manufacturers. The court determined the lawsuits from Bayer CropScience LLC against the companies will continue to the next phase of litigation.
Timeline
A federal judge rejected the dismissal requests on September 28, 2026.
The Tech Race
This legal battle highlights the intensifying competition over the foundational intellectual property that defines modern biotechnology. As companies pivot toward mRNA-based solutions, legal challenges will likely continue to shape the trajectory of biotech innovation and industry dominance.
These legal developments may influence the future pricing and availability of advanced mRNA therapeutics for consumers. While the litigation proceeds, users and healthcare providers are unlikely to see immediate changes to current medical access.
The takeaway
The court's decision ensures that the underlying patent disputes will undergo further judicial scrutiny. Investors and industry stakeholders should monitor the litigation as it could set a critical precedent for mRNA technology rights.
Further reading
For broader context on current industry developments, visit the Biotech section.
Live Poll
Do patent lawsuits against vaccine manufacturers decrease your trust in pharmaceutical companies?
